{"disease":{"id":"covid-19-severe-pneumonia","name":"covid 19 severe pneumonia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04474340","title":"COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Ministry of Health, Kuwait","has_results":false},{"nct_id":"NCT04369469","title":"Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":202,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04435223","title":"Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen","phase":"","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Centre Hospitalier Universitaire Dijon","has_results":false},{"nct_id":"NCT04412668","title":"Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"aTyr Pharma, Inc.","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}